This is our library on scientific research related to CBD, the Endocannabinoid System, other cannabinoids and Irritable Bowel Syndrome. Below you will find a list of conditions for which there are one or more scientific studies of CBD. The source of these scientific studies relates primarily to PubMed, an online service of the U.S. National Library of Medicine.
Important: The studies that are listed by PubMed are for the most part preclinical research. These relate in most cases to animal experiments with isolated CBD (pure CBD) and not fully extracted CBD extract. Although mammals have cell receptors that respond to cannabinoid compounds, the data collected from animal studies are not always 1: 1 applicable to humans. Always check with your physician before starting a new dietary supplement program. Learn more at: The Basics of CBD Oils and Cannabis as a Therapeutic Agent
- Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease (Biochemical Pharmacology)
- Cannabidiol in inflammatory bowel diseases: A brief overview
- Cannabinoid actions at TRPV channels: Effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation
- Cannabinoids and GI Disorders: Endogenous and Exogenous
- CBD and gastrointestinal motility
- CBD and the gut: New developments and emerging concepts
- CBD reduces intestinal inflammation through the control of neuroimmune axis
- Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?
- Endocannabinoids and the gastrointestinal tract
- Getting into the weed: the role of the endocannabinoid system in the brain-gut axis
- Therapeutic potential of cannabinoid-based drugs